Plasma HIV RNAandCD4+ cell count data obtained within the last 6 months and type of assay were abstracted from medical records. Because of the variability in type of assay used across the study sites (ie, Versant HIV-1 RNA 3.0 [Siemens Diagnostics]; Amplicor HIV-1 Monitor – Standard/Ultrasensitive [F. Hoffmann-La Roche Ltd]; COBAS AmpliPrep/COBAS Taqman HIV-1 Test, versions 1.0 and 2.0 [F. Hoffmann-La Roche Ltd]; and RealTime HIV-1 Assay [Abbott Laboratories]), we used the corresponding assay cutoff for the lower limit of HIV RNA detection (all were <200 copies/mL; see Kahana et al11 (link) for sensitivity analysis) and created a dichotomous variable to differentiate VL− and VL+ participants.